AR034098A1 - Derivados piperidin-4-carboxamidas, composiciones farmaceuticas y el uso de las mismas para la preparacion de un medicamento para el tratamiento de los trastornos mediados por integrina - Google Patents
Derivados piperidin-4-carboxamidas, composiciones farmaceuticas y el uso de las mismas para la preparacion de un medicamento para el tratamiento de los trastornos mediados por integrinaInfo
- Publication number
- AR034098A1 AR034098A1 ARP000105121A ARP000105121A AR034098A1 AR 034098 A1 AR034098 A1 AR 034098A1 AR P000105121 A ARP000105121 A AR P000105121A AR P000105121 A ARP000105121 A AR P000105121A AR 034098 A1 AR034098 A1 AR 034098A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- aryl
- optionally substituted
- substituted
- heteroaryl
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229940126601 medicinal product Drugs 0.000 title 1
- 125000001424 substituent group Chemical group 0.000 abstract 12
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 9
- 125000003118 aryl group Chemical group 0.000 abstract 7
- 125000001072 heteroaryl group Chemical group 0.000 abstract 7
- 229910052739 hydrogen Inorganic materials 0.000 abstract 7
- 239000001257 hydrogen Substances 0.000 abstract 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 5
- 208000035475 disorder Diseases 0.000 abstract 5
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical group 0.000 abstract 4
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 3
- 125000002947 alkylene group Chemical group 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- -1 R3HN- Chemical group 0.000 abstract 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 2
- 125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 125000000732 arylene group Chemical group 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 125000004385 trihaloalkyl group Chemical group 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 abstract 1
- DPBWFNDFMCCGGJ-UHFFFAOYSA-N 4-Piperidine carboxamide Chemical class NC(=O)C1CCNCC1 DPBWFNDFMCCGGJ-UHFFFAOYSA-N 0.000 abstract 1
- 206010002388 Angina unstable Diseases 0.000 abstract 1
- 206010003178 Arterial thrombosis Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000006386 Bone Resorption Diseases 0.000 abstract 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 abstract 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 abstract 1
- 208000002249 Diabetes Complications Diseases 0.000 abstract 1
- 206010012655 Diabetic complications Diseases 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 208000007814 Unstable Angina Diseases 0.000 abstract 1
- 206010047249 Venous thrombosis Diseases 0.000 abstract 1
- 206010000891 acute myocardial infarction Diseases 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000004450 alkenylene group Chemical group 0.000 abstract 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 238000002399 angioplasty Methods 0.000 abstract 1
- 239000003146 anticoagulant agent Substances 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 230000024279 bone resorption Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001721 carbon Chemical group 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 102000006495 integrins Human genes 0.000 abstract 1
- 108010044426 integrins Proteins 0.000 abstract 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 230000009424 thromboembolic effect Effects 0.000 abstract 1
- 230000002537 thrombolytic effect Effects 0.000 abstract 1
- 125000004952 trihaloalkoxy group Chemical group 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
- 230000003966 vascular damage Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Derivados piperidin-4-carboxamidas de fórmula (1) en donde R1, R2, R6, L, M, N, Q, W, r tienen su significado dado más abajo. Además se describe una composición farmacéutica y el uso de dichos derivados para la preparación de un medicamento para tratar trastornos mediados por la integrina que se selecciona del grupo formado por restenosis, angina inestable, trastornos tromboembólicos, dano vascular, aterosclerosis, trombosis arterial, trombosis venosa, trastornos vaso-oclusivos, infarto agudo del miocardio, re-oclusión luego de la terapia trombolítica, re-oclusión luego de angioplastía, inflamación, artritis reumatoidea, osteoporosis, trastornos de reabsorción ósea, cáncer, crecimiento tumoral, angiogénesis, esclerosis múltiple, trastornos neurológicos, asma, degeneración macular, complicaciones diabéticas y retinopatía diabética. Donde en la fórmula (1): M se selecciona de alquileno C1-4 (opcionalmente sustituido dentro de la cadena de carbono con un sustituyente seleccionado de alquilo C1-4, alquenilo C2-4, cicloalquilo (donde un átomo de carbono del anillo forma el punto de enlace a la cadena de carbono) o arilo (opcionalmente sustituido con halógeno) y sustituido sobre el carbono terminal con un sustituyente seleccionado de A), alquenileno C2-4 (sustituido con un sustituyente seleccionado de A), heterociclileno (opcionalmente sustituido con un sustituyente seleccionado de A), heterociclenileno (sustituido con un sustituyente seleccionado de A), arileno (sustituido con un sustituyente seleccionado de A), (alquilen C1-4)arilo (sustituido sobre el alquileno C1-4 con un sustituyente seleccionado de A) o arilenalquilo (C1-4) (sustituido sobre arileno con un sustituyente seleccionado de A); A está opcionalmente presente y se selecciona de heteroarilo, heterociclilo, R3HN-(heteroaril)amino, (heterociclil)amino, R3HNC(=NH)-, R3NHC(=NH)NH-, R3HNC(=O)NH-, R3C(=NH)NH-, (heterociclil)aminoxi, (heteroaril)aminoxi, R3HNC(=NH)NHO-, R3C(=NH)NHO-, R3HNC(=NH)NHC(=O)-, R3C(=NH)NHC(=O)-, donde heteroarilo y heterociclilo están opcionalmente sustituido con entre uno y cinco sustituyentes independientemente seleccionados de alquilo C1-4, alcoxi C1-4, heteroarilo (opcionalmente sustituido con alquilo C1-4), halógeno, hidroxilo, nitro, ciano, trihaloalquilo C1-4, alquilcarbonilo C1-4, alcoxicarbonilo C1-4, aril(C1-4)alcoxicarbonilo, R3HN-, aminoalquilo (C1-4), alquil (C1-4)-aminoalquilo (C1-4) o di(alquil C1-4)aminoalquilo (C1-4); con la condición de que, si A es H2NH(=NH)NH-, entonces, de manera dependiente, W no es hidrógeno cuando Q es -CH2-; L se selecciona de -C(=O)-, -SO2-, -OC(=O) o -NHC(=O)-; R1 se selecciona de hidrógeno, alquilo C1-8 o cicloalquilo; R2 se selecciona de hidrógeno o alquilo C1-8; R3 se selecciona de hidrógeno, alquilo C1-8, arilo, arilalquilo (C1-8), cicloalquilo, hidroxilo, ciano o nitro; Q se selecciona de -CH2-, -CH(alquilo C1-8)-, -CH(alquenilo C2-8)-, -CH(alquinilo C2-8)-, -CH(arilo)- (donde arilo está opcionalmente sustituido con entre de uno a cinco sustituyentes independientemente seleccionados de alquilo C1-4, alcoxi C1-4, -O-(alquilo C1-3)-O-, halógeno, hidroxi, trihaloalquilo (C1-3) o trihaloalcoxi (C1-3), -CH(heteroarilo)- (donde heteroarilo está opcionalmente sustituido con un sustituyente seleccionado de halógeno, hidroxi, alquilo C1-4, alcoxi C1-4, -O-(alquilo C1-3)-O-, amino, alquilamino C1-4 o dialquil(C1-4)amino o -CH(arilalquilo (C1-8))-; W se selecciona de hidrógeno o N(R4)T; r es un entero seleccionado de 0 ó 1; R4 se selecciona de hidrógeno, alquilo C1-8 o acilo C2-6; T se selecciona de R5C(=O)-, R5OC(=O)- o R5C(=N-CN)-; R5 se selecciona de alquilo C1-6, arilo, arilalquilo (C1-8) o amino (donde amino está opcionalmente sustituido con entre uno y dos sustituyentes independientemente seleccionados de alquilo C1-8); R6 se selecciona de hidrógeno, alquilo C1-8, arilalquilo (C1-8), (R7)N-alquilo (C1-8), (R8)(R7)Nalquilo (C1-8), o (R8)(R7)NC(=O)alquilo (C1-8); y R7 y R8 se seleccionan independientemente de hidrógeno, alquilo C1-8 o cicloalquilo; y sus sales farmacéuticamente aceptables.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15661799P | 1999-09-29 | 1999-09-29 | |
| US66713400A | 2000-09-21 | 2000-09-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR034098A1 true AR034098A1 (es) | 2004-02-04 |
Family
ID=26853350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000105121A AR034098A1 (es) | 1999-09-29 | 2000-09-28 | Derivados piperidin-4-carboxamidas, composiciones farmaceuticas y el uso de las mismas para la preparacion de un medicamento para el tratamiento de los trastornos mediados por integrina |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7718673B2 (es) |
| EP (1) | EP1133489B9 (es) |
| CN (1) | CN1352641A (es) |
| AR (1) | AR034098A1 (es) |
| AT (1) | ATE300531T1 (es) |
| AU (1) | AU7711000A (es) |
| BR (1) | BR0007183A (es) |
| CA (1) | CA2352957A1 (es) |
| CZ (1) | CZ20011872A3 (es) |
| DE (2) | DE60021521T4 (es) |
| ES (1) | ES2244474T3 (es) |
| HU (1) | HUP0200439A2 (es) |
| NO (1) | NO20012612L (es) |
| NZ (1) | NZ511997A (es) |
| PL (1) | PL347976A1 (es) |
| RU (1) | RU2001114518A (es) |
| WO (1) | WO2001023376A1 (es) |
| YU (1) | YU22802A (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0731088B1 (en) | 1990-11-19 | 2000-10-04 | Monsanto Company | Retroviral protease inhibitors |
| CA2492035A1 (en) | 2002-07-11 | 2004-01-15 | Vicuron Pharmaceuticals, Inc. | N-hydroxyamide derivatives possessing antibacterial activity |
| US20040224986A1 (en) | 2002-08-16 | 2004-11-11 | Bart De Corte | Piperidinyl targeting compounds that selectively bind integrins |
| RS52918B (en) | 2004-04-02 | 2014-02-28 | The Regents Of The University Of California | PROCEDURES AND MIXTURES FOR TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH ALFA V BETA 5 INTEGRINE |
| EP2285372A2 (en) * | 2008-05-16 | 2011-02-23 | Allergan, Inc. | Selective subtype alpha 2 adrenergic agents and methods for use thereof |
| CN102481347A (zh) | 2009-07-24 | 2012-05-30 | 加州大学董事会 | 治疗和预防整合素αvβ5相关疾病的方法及组合物 |
| EP3565811A1 (en) * | 2017-01-09 | 2019-11-13 | Ardelyx, Inc. | Inhibitors of nhe-mediated antiport |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2830555A1 (de) | 1978-07-12 | 1980-03-06 | Bayer Ag | Chinazolinonyl-verbindungen |
| GB8829296D0 (en) | 1988-12-15 | 1989-01-25 | Ici Plc | Anti-tumour compounds |
| JPH04334357A (ja) * | 1991-05-02 | 1992-11-20 | Fujirebio Inc | 酵素阻害作用を有するアシル誘導体 |
| CA2117282A1 (en) | 1991-11-22 | 1993-05-27 | Ofer Lider | Non-peptidic surrogates of the arg-gly-asp sequence and pharmaceutical compositions comprosing them |
| DE4208051A1 (de) * | 1992-03-13 | 1993-09-16 | Bayer Ag | Substituierte phenylessigsaeureamide |
| CA2150550A1 (en) | 1992-12-01 | 1994-06-09 | Melissa S. Egbertson | Fibrinogen receptor antagonists |
| US6268380B1 (en) | 1993-02-19 | 2001-07-31 | G. D. Searle & Co. | Urea derivatives useful as platelet aggregation inhibitors |
| DE4309867A1 (de) | 1993-03-26 | 1994-09-29 | Cassella Ag | Neue Harnstoffderivate, ihre Herstellung und Verwendung |
| GB9313268D0 (en) | 1993-06-28 | 1993-08-11 | Zeneca Ltd | Chemical compounds |
| ES2164109T3 (es) | 1993-09-22 | 2002-02-16 | Fujisawa Pharmaceutical Co | Derivados de n-(3-piperidinilcarbonil)-beta-alanina como antagonistas de paf. |
| WO1995032710A1 (en) | 1994-05-27 | 1995-12-07 | Merck & Co., Inc. | Compounds for inhibiting osteoclast-mediated bone resorption |
| US5700801A (en) * | 1994-12-23 | 1997-12-23 | Karl Thomae, Gmbh | Piperazine derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
| CN1183770A (zh) * | 1994-12-23 | 1998-06-03 | 卡尔·托马博士公司 | 哌嗪衍生物,含该化合物的药物,其用途以及制法 |
| US5602155A (en) | 1995-01-17 | 1997-02-11 | G. D. Searle & Co. | Platelet aggregation inhibitors |
| CN1313146C (zh) | 1995-08-14 | 2007-05-02 | 斯克里普斯研究学院 | 用于抑制αvβ5介导的血管生成的方法和组合物 |
| US6100423A (en) | 1995-08-30 | 2000-08-08 | G. D. Searle & Co. | Amino benzenepropanoic acid compounds and derivatives thereof |
| DE69613985T2 (de) | 1995-08-30 | 2002-06-13 | G.D. Searle & Co., Chicago | Meta-guanidine, harnstoff, thioharnstoff oder azacyklische aminobenzoesäure-derivate als integrin antagonisten |
| WO1997015567A1 (de) | 1995-10-20 | 1997-05-01 | Dr. Karl Thomae Gmbh | 5-gliedrige heterocyclen, diese verbindungen enthaltende arzneimittel und deren verwendung sowie verfahren zu ihrer herstellung |
| DE19548709A1 (de) | 1995-12-23 | 1997-07-03 | Merck Patent Gmbh | Tyrosinderivate |
| WO1997036859A1 (en) | 1996-03-29 | 1997-10-09 | G.D. Searle & Co. | Para-substituted phenylpropanoic acid derivatives as integrin antagonists |
| PT923555E (pt) | 1996-05-01 | 2005-09-30 | Ortho Mcneil Pharm Inc | Derivados carboxamida de pirrolidina, piperidina e hexa-hidroazepina para o tratamento de disturbios tromboticos |
| DE19642591A1 (de) | 1996-10-15 | 1998-04-16 | Basf Ag | Neue Piperidin-Ketocarbonsäure-Derivate, deren Herstellung und Anwendung |
| JP3841898B2 (ja) * | 1996-11-21 | 2006-11-08 | 三菱電機株式会社 | 深部線量測定装置 |
| AU5596298A (en) | 1996-12-09 | 1998-07-03 | Cor Therapeutics, Inc. | Integrin antagonists |
| AR011913A1 (es) | 1997-03-06 | 2000-09-13 | Yamano Masaki | Derivados de 4,4-difluoro-2,3,4,5-tetrahidro-1h-1-benzoazepina y composiciones farmaceuticas de los mismos. |
| CN1280574A (zh) | 1997-10-27 | 2001-01-17 | 雷迪研究基金会 | 新的杂环化合物及其在医药中的应用、它们的制备方法和含有它们的药物组合物 |
| US6066651A (en) | 1997-10-29 | 2000-05-23 | Ortho-Mcneil Pharmaceutical, Inc. | Orally-active nipecotamide glycolamide esters for the treatment of thrombosis disorders |
| AU1415099A (en) | 1997-11-18 | 1999-06-07 | Merck & Co., Inc. | 4-substituted-4-piperidine carboxamide derivatives |
| JP2003504301A (ja) | 1998-04-01 | 2003-02-04 | ブリストル−マイヤーズ スクイブ ファーマ カンパニー | インテグリンアンタゴニスト |
| JP4142253B2 (ja) | 1998-05-11 | 2008-09-03 | ノボ ノルディスク アクティーゼルスカブ | 成長ホルモン放出特性を有する化合物 |
| TW591026B (en) * | 1998-06-23 | 2004-06-11 | Upjohn Co | Inhibitors of alpha4beta1 mediated cell adhesion |
| US6388054B1 (en) | 1998-08-20 | 2002-05-14 | John M. Stewart | Anti-cancer compounds |
| WO2000033836A1 (en) | 1998-12-04 | 2000-06-15 | Ontogen Corporation | 5-membered heterocycles for the treatment of human diseases involving modulators of selectins |
| WO2001010867A1 (en) | 1999-08-06 | 2001-02-15 | Smithkline Beecham Corporation | Vitronectin receptor antagonists useful for the treatment of strokes |
| MXPA02001518A (es) | 1999-08-10 | 2002-07-02 | Procter & Gamble | Detergente liquido no acuoso con particulas de llenador de baja densidad y solubles en agua. |
-
2000
- 2000-09-22 CA CA002352957A patent/CA2352957A1/en not_active Abandoned
- 2000-09-22 EP EP00966823A patent/EP1133489B9/en not_active Expired - Lifetime
- 2000-09-22 PL PL00347976A patent/PL347976A1/xx not_active Application Discontinuation
- 2000-09-22 CN CN00803033A patent/CN1352641A/zh active Pending
- 2000-09-22 HU HU0200439A patent/HUP0200439A2/hu unknown
- 2000-09-22 CZ CZ20011872A patent/CZ20011872A3/cs unknown
- 2000-09-22 RU RU2001114518/04A patent/RU2001114518A/ru not_active Application Discontinuation
- 2000-09-22 AU AU77110/00A patent/AU7711000A/en not_active Abandoned
- 2000-09-22 BR BR0007183-8A patent/BR0007183A/pt not_active IP Right Cessation
- 2000-09-22 AT AT00966823T patent/ATE300531T1/de not_active IP Right Cessation
- 2000-09-22 NZ NZ511997A patent/NZ511997A/xx unknown
- 2000-09-22 ES ES00966823T patent/ES2244474T3/es not_active Expired - Lifetime
- 2000-09-22 WO PCT/US2000/026163 patent/WO2001023376A1/en active IP Right Grant
- 2000-09-22 DE DE60021521T patent/DE60021521T4/de not_active Expired - Lifetime
- 2000-09-22 DE DE60021521A patent/DE60021521D1/de not_active Expired - Fee Related
- 2000-09-28 AR ARP000105121A patent/AR034098A1/es unknown
- 2000-09-29 YU YU22802A patent/YU22802A/sh unknown
-
2001
- 2001-05-28 NO NO20012612A patent/NO20012612L/no not_active Application Discontinuation
-
2003
- 2003-01-16 US US10/345,808 patent/US7718673B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1133489B9 (en) | 2006-05-03 |
| ES2244474T3 (es) | 2005-12-16 |
| RU2001114518A (ru) | 2003-04-20 |
| YU22802A (sh) | 2005-06-10 |
| EP1133489B1 (en) | 2005-07-27 |
| US7718673B2 (en) | 2010-05-18 |
| CN1352641A (zh) | 2002-06-05 |
| AU7711000A (en) | 2001-04-30 |
| WO2001023376A1 (en) | 2001-04-05 |
| DE60021521D1 (de) | 2005-09-01 |
| ATE300531T1 (de) | 2005-08-15 |
| NO20012612D0 (no) | 2001-05-28 |
| NO20012612L (no) | 2001-07-17 |
| CA2352957A1 (en) | 2001-04-05 |
| NZ511997A (en) | 2004-12-24 |
| HUP0200439A2 (en) | 2002-06-29 |
| CZ20011872A3 (cs) | 2002-03-13 |
| BR0007183A (pt) | 2002-02-05 |
| EP1133489A1 (en) | 2001-09-19 |
| DE60021521T4 (de) | 2006-09-21 |
| US20030181440A1 (en) | 2003-09-25 |
| PL347976A1 (en) | 2002-05-06 |
| DE60021521T2 (de) | 2006-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20050016L (no) | Difenylazetidinonderivater for behandling av forstyrrelser i lipid metabolismen | |
| AR035216A1 (es) | Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios | |
| AR052328A1 (es) | Derivados de 2 - alcoxi - 3, 4, 5 - trihidroxi - alquilamidas, composiciones farmaceuticas que las contienen, y su uso en la fabricacion de un medicamento para el tratamiento del cancer. | |
| DK0751934T3 (da) | Substituerede azetidinonforbindelser, der kan anvendes som hypocholesterolæmiske midler | |
| AR035320A1 (es) | Compuestos activadores de hppardelta, composicion farmaceutica, su uso en la preparacion de medicamentos, metodo para el tratamiento de enfermedades mediadas por hppardelta | |
| TR200003478T2 (tr) | Antikanser maddeleri olarak faydalı izotiyazol türevleri | |
| AR003936A1 (es) | Compuestos triciclicos y composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de un medicamento util para inhibir elcrecimiento anormal de celulas. | |
| AR088808A2 (es) | Derivados de 2h-piridazin-3-ona, composiciones farmaceuticas que los contienen y un proceso para la preparacion de dichos derivados y el uso de dichos derivados para la preparacion de una composicion farmaceutica | |
| AR029634A1 (es) | Compuestos derivados heterociclicos utiles como agentes anticancerosos, composicion farmaceutica y procedimiento de tratamiento | |
| AR037517A1 (es) | Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria | |
| HUT61312A (en) | Process for producing pyrazolopyrimidinones and pharmaceutical compositions comprising such compounds | |
| AR033525A1 (es) | Arilmetilaminas sustituidas, composiciones farmaceuticas, uso de las mismas para la manufactura de un medicamento | |
| NO2005024I2 (no) | Ester av 5-aminolevulinsyre som fotosensibiliseringsmiddel i fotokjemoterapi, anvendelse derav, samtfarmasoytisk blanding, produkt, utstyrsett og fre mgangsmaate for in vitro-diagnostisering | |
| HUP0204157A2 (hu) | Új 1,3-dihidro-2H-indol-2-on-származékok, eljárás a vegyületek előállítására és a vegyületeket tartalmazó gyógyászati készítmények | |
| HUP0101999A2 (hu) | 4-Hidroxi-kinolin-3-karboxamid- és -hidrazid-származékok, ezeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása | |
| PA8511201A1 (es) | Derivados de nicotinamida benzocondensada-heterociclilo utiles como inhibidores selectivos de las isozimas pde4 | |
| AR034098A1 (es) | Derivados piperidin-4-carboxamidas, composiciones farmaceuticas y el uso de las mismas para la preparacion de un medicamento para el tratamiento de los trastornos mediados por integrina | |
| AR057576A1 (es) | Derivados sustituidos de pirrolidin-quinazolinas inhibidores de canales de sodio dependientes de voltaje, composiciones farmaceuticas que los contienen y usos, entre otros, en el tratamiento de una variedad de condiciones de dolor | |
| CO5540385A2 (es) | Derivados quirales de acido oxazol arilpropionico, su metodo de sintesis ycomposiciones farmaceuticas que los contienen | |
| AR043062A1 (es) | Ureas sustituidas y carbamatos utiles para el tratamiento de la enfermedad de alzheimer | |
| AR036094A1 (es) | Compuestos derivados de acido sulfonico, composicion farmaceutica y su uso en la preparacion de medicamentos | |
| AR034204A1 (es) | Composiciones y combinaciones de acido nicotinico y derivados del mismo con inhibidor(es) de la absorcion de los esteroles, y el uso de los mismos para preparar medicamentos para el tratamiento para indicaciones vasculares | |
| PT98371A (pt) | Processo para a preparacao de derivados 6-alcoxi de arabinofuranosil-guanina e de composicoes farmaceuticas que os contem | |
| CO5560569A2 (es) | Productos de combinacion de derivados de propanolamina arilo sustituidos con otros ingredientes activos y su uso | |
| AR032622A1 (es) | Compuestos de 4-amino-azepan-3-ona, composiciones farmaceuticas que los comprenden, intermediarios utiles en la sintesis de tales compuestos, procedimiento para la sintesis de dichos compuestos, y uso de tales compuestos en la fabricacion de medicamentos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |